| | 862507-23-1 Basic information More.. |
| Product Name: | LY2228820 | | Synonyms: | 5-(2-tert-butyl-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate;5-(2-(tert-butyl)-5-(4-fluorophenyl)-1H-imidazol-4-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-amine dimethanesulfonate;LY2228820;LY 2228820;LY-2228820;5-(2-tert-Butyl-5-(4-fluorophenyl)-1H-imidazol-4-yl)-3-neopentyl-3H-imidazo[4,5-b]pyridin-2-am;LY2228820;5-[2-(1,1-DiMethylethyl)-5-(4-fluorophenyl)-1H-iMidazol-4-yl]-3-(2,2-diMethylpropyl)-3H-iMidazo[4,5-b]pyridin-2-aMine DiMethanesulfonate;LY2228820(LY-2228820);LY2228820 2MsOH | | CAS: | 862507-23-1 | | MF: | C26H37FN6O6S2 | | MW: | 612.7369832 | | EINECS: | | | Mol File: | 862507-23-1.mol |  |
Use
LY2228820 is a novel and potent p38MAPK inhibitor with potent antiinflammatory activity. LY2228820 significantly inhibited phosphorylation of MAPKAPK2 and/or HSP27, down stream targets of p38MAPK, in both multiple myeloma (MM) cell lines and LT-BMSCs. LY2228820 is a potential candidate to improve MM patient outcome both by enhancing the effect of Bortezomib (B675700) and by reducing osteoskeletal events.
- LY2228820
-
- US $1.00 / g
- 2020-01-13
- CAS:862507-23-1
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 200kg
|
|
862507-23-1
Recommend Suppliers |
|